The long-term trend of the EPS is a vital number as it helps understand the future potential of Checkpoint Therapeutics. The EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been -59.30 % over the last twelve months. The long-term trend in EPS shows how well the management of Checkpoint Therapeutics is adding value for shareholders.
Checkpoint Therapeutics trades as part of the biotechnology industry and trades as part of the healthcare sector. The company CEO is James F. Oliviero. Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company which focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers.
Previous Intraday Performance:
The CKPT shares had a previous change of -5.82% which opened at 2.59 and closed at 2.46. It moved to an intraday high of 2.70 and a low of 2.35.
SeekingAlpha: FBIOP: A Speculative 13.3% Yielder From A Company With More Cash Than Debt
Historical Performance:
Over the last five trading days, CKPT shares returned 14.95% and in the past 30 trading days it returned -11.51%. Over three months, it changed -36.60%. In one year it has changed -38.35% and within that year its 52-week high was 6.50 and its 52-week low was 1.89. CKPT stock is 30.11% above its 52 Week Low.
Our calculations result in a 200 day moving average of 3.46 and a 50 day moving average of 2.78. Right now, CKPT stock is trading -28.81% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
SeekingAlpha: FBIOP: A Speculative 13.3% Yielder From A Company With More Cash Than Debt
Liquidity:
The company has a market cap of $79.0m with 32.1m shares outstanding and a float of 30.0m shares. Trading volume was 59,176 shares and has experienced an average volume of 48,922 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Checkpoint Therapeutics was -1 which ended on 31st of December 2017. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.22.
Below was the last reported quarterly earnings per share:
09-30-2018: -0.32
06-30-2018: -0.23
03-31-2018: -0.35
12-31-2017: -0.26
Indicators Also to Watch:
Based on the latest filings, there is 6.40% of insider ownership and 1.60% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.
I calculated the beta to be 2.92
SeekingAlpha: Apellis Pharma down 17% on hiccup in late-stage study of APL-2
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -146.60%, return on assets is -108.63%, price-to-sales is 103.92 and price-to-book is 5.59.
Company Score Card:
Results are out of six:
0 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result
Related Tags: Biotechnology, Checkpoint Therapeutics, CKPT, Healthcare
